In September 2014, it was announced that Calico, in partnership with AbbVie, would be opening up an R&D facility focused on aging and age-related diseases, such as neurodegeneration and cancer.[9] Initially, each company will invest $350 million, with an option for each to add an extra $500 million later on.[10] In the same month, Calico announced a partnership with the University of Texas Southwestern Medical Center and 2M Companies regarding drug development for neurodegenerative disorders.[11]